Its active ingredient, tirzepatide, is also approved for weight loss under the brand name Zepbound
--- ## Retatrutide FDA Approval Timeline: What to Expect As of July 2026, Eli Lilly's TRIUMPH Phase 3 program is underway with four trials (TRIUMPH-1 through TRIUMPH-4) covering obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH)
Therefore, well-designed studies that adjust for these variables provide more reliable safety signals than early uncontrolled analyses
Dihexa takes an entirely different route
Radiofrequency Ablation Therapy Radiofrequency ablation has become a standard treatment for various conditions, including cardiac arrhythmias, liver tumours, and chronic pain conditions
Both genders exceeded 20% total body weight reduction, which represents a clinical threshold where obesity-related health markers show dramatic improvement